Search Results - "Le Loarer, F"

Homogeneous myxoid liposarcomas mimicking cysts on MRI: A challenging diagnosis by Crombé, A., Loarer, F. Le, Alberti, N., Buy, X., Stoeckle, E., Cousin, S., Toulmonde, M., Coindre, J.M., Italiano, A., Kind, M.

“…Myxoid liposarcoma (M-LPS) is the second most frequent subtype of liposarcoma. Foci of fat on MRI are strongly suggestive of this diagnosis. The aims of this…”
Get full text

The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: long term results from a monocentric series by Stoeckle, Eberhard, Dr, Michot, Audrey, MD, Regal, Leslie, MSc, Babre, Florence, MD, Sargos, Paul, MD, Henriques de Figueiredo, Bénédicte, MD, Brouste, Véronique, MSc, Italiano, Antoine, MD, PhD, Toulmonde, Maud, MD, Le Loarer, François, MD, PhD, Kind, Michèle, MD

“…Abstract Background and objectives Conservative surgery for soft-tissue sarcoma (STS) within multimodality treatment attempts to reconcile two contradictory…”
Get full text

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort by Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., Fridman, W. H.

“…Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that…”
Get full text

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study by Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., Fridman, W.H., Sautes-Fridman, C., Kind, M., Le Loarer, F., Pulido, M., Italiano, A.

“…There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. This was an open-label, multicentre,…”
Get full text

Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer by Brunet, M., Crombé, A., Cousin, S., Vanhersecke, L., Le Loarer, F., Bessede, A., Italiano, A.

Get full text

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance by Loriot, Y., Marabelle, A., Guégan, J.P., Danlos, F.X., Besse, B., Chaput, N., Massard, C., Planchard, D., Robert, C., Even, C., Khettab, M., Tselikas, L., Friboulet, L., André, F., Nafia, I., Le Loarer, F., Soria, J.C., Bessede, A., Italiano, A.

“…Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a…”
Get full text

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors by Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F., Le Loarer, F., Chaput, N., Danlos, F.-X., Planchard, D., Even, C., Khettab, M., Tselikas, L., Besse, B., Barlesi, F., Soria, J.-C., Marabelle, A., Bessede, A., Italiano, A.

“…The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do…”
Get full text

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years by Blay, JY, Piperno-Neumann, S., Watson, S., Dufresne, A., Valentin, T., Duffaud, F., Toulmonde, M., Italiano, A., Bertucci, F., Tlemsani, C., Firmin, N., Bompas, E., Perrin, C., Ropars, M., Saada-Bouzid, E., Dubray-Longeras, P., Hervieu, A., Lebbe, C., Gantzer, J., Chaigneau, L., Fiorenza, F., Rios, M., Isambert, N., Soibinet, P., Boudou-Roquette, P., Verret, B., Ferron, G., Ryckewaert, T., Lebellec, L., Brahmi, M., Gouin, F., Meeus, P., Vaz, G., Le Loarer, F., Karanian, M., De Pinieux, G., Ducimetiere, F., Chemin, C., Morelle, M., Le Cesne, A., Penel, N.

“…Epithelioid hemangioendothelioma (EHE) is an ultrarare sarcoma whose natural history and treatment is not well defined. We report on the presentation and…”
Get full text

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years by Blay, J Y, Tlemsani, C, Toulmonde, M, Italiano, A, Rios, M, Bompas, E, Valentin, T, Duffaud, F, Le Nail, L R, Watson, S, Firmin, N, Dubray-Longeras, P, Ropars, M, Perrin, C, Hervieu, A, Lebbe, C, Saada-Bouzid, E, Soibinet, P, Fiorenza, F, Bertucci, F, Boudou, P, Vaz, G, Bonvalot, S, Honoré, C, Marec-Berard, P, Minard, V, Cleirec, M, Biau, D, Meeus, P, Babinet, A, Dumaine, V, Carriere, S, Fau, M, Decanter, G, Gouin, F, Ngo, C, Le Loarer, F, Karanian, M, Meurgey, A, Dufresne, A, Brahmi, M, Chemin-Airiau, C, Ducimetiere, F, Penel, N, Le Cesne, A

“…Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas sharing common translocations whose natural history…”
Get full text

CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications by Laroche-Clary, A., Lucchesi, C., Rey, C., Verbeke, S., Bourdon, A., Chaire, V., Algéo, M.-P., Cousin, S., Toulmonde, M., Vélasco, V., Shutzman, J., Savina, A., Le Loarer, F., Italiano, A.

“…Inhibition of ChK1 appears as a promising strategy for selectively potentiate the efficacy of chemotherapeutic agents in G1 checkpoint-defective tumor cells…”
Get full text

Pre- or postoperative radiotherapy for soft tissue sarcomas by Llacer-Moscardo, C., Terlizzi, M., Bonvalot, S., Le Loarer, F., Carrère, S., Tetrau, R., D’ascoli, A., Lerouge, D., Le Péchoux, C., Thariat, J.

“…Sarcomas are rare tumours arising from mesenchymal tissue. A multimodal management in an expert centre combining surgery and radiotherapy is the current…”
Get full text

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas by Brahmi, M., Lesluyes, T., Dufresne, A., Toulmonde, M., Italiano, A., Mir, O., Le Cesne, A., Valentin, T., Chevreau, C., Bonvalot, S., Penel, N., Coindre, J.-M., Le Guellec, S., Le Loarer, F., Karanian, M., Blay, J.-Y., Chibon, F.

“…While the anti-PDGFRA antibody olaratumab failed to confirm an impact on survival in unselected advanced soft tissue sarcoma (STS) patients, the level of…”
Get full text

Surgery in reference centers improves survival of sarcoma patients: a nationwide study by Blay, J.-Y., Honoré, C., Stoeckle, E., Meeus, P., Jafari, M., Gouin, F., Anract, P., Ferron, G., Rochwerger, A., Ropars, M., Carrere, S., Marchal, F., Sirveaux, F., Di Marco, A., Le Nail, L.R., Guiramand, J., Vaz, G., Machiavello, J.-C., Marco, O., Causeret, S., Gimbergues, P., Fiorenza, F., Chaigneau, L., Guillemin, F., Guilloit, J.-M., Dujardin, F., Spano, J.-P., Ruzic, J.-C., Michot, A., Soibinet, P., Bompas, E., Chevreau, C., Duffaud, F., Rios, M., Perrin, C., Firmin, N., Bertucci, F., Le Pechoux, C., Le Loarer, F., Collard, O., Karanian-Philippe, M., Brahmi, M., Dufresne, A., Dupré, A., Ducimetière, F., Giraud, A., Pérol, D., Toulmonde, M., Ray-Coquard, I., Italiano, A., Le Cesne, A., Penel, N., Bonvalot, S.

“…NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of…”
Get full text

1525TiP TORNADO: A randomized multicenter open-label phase II study evaluating retifanlimab in combination with neoadjuvant chemotherapy in patients with selected retroperitoneal sarcomas by Albert, S., Italiano, A., Toulmonde, M., Cousin, S., Bahleda, R., Brahmi, M., Watson, S., Auzanneau, C., Douiri, N., Poignie, L., Lortal, B., Le Loarer, F., Bellera, C.

Get full text

1921MO Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG) by Vanacker, H., Le Loarer, F., Karanian, M., Meurgey, A., Dufresne, A., El Zein, S., Blay, J-Y., Collard, O., Ray-Coquard, I.L., Waissi, W.A., Pissaloux, D., Paindavoine, S., Houlier, A., Pierron, G., Meeus, P., Tirode, F., Brahmi, M.

Get full text

1955P Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning by Karanian, M., Camara, A., Klein, J., Marchand, T., Maussion, C., Rousseau, V., Bonnotte, T., Perret, R., Le Loarer, F., Ngo, C., Korbi, S., Mansour, Y., Meurgey, A., Jean-Denis, M., Italiano, A., Blay, J-Y., Coindre, J.M.

Get full text

Severe drug eruption caused by a medication error by Le Loarer, F, Carré-Gislard, D, Baricault, S, Bravard, P

Get full text

1527TiP CONGRATS-combination of nivolumab plus relatlimab in patients with advanced or metastatic soft-tissue sarcoma: A proof-of-concept randomized phase II study by Spalato Ceruso, M., Albert, S., Italiano, A., Toulmonde, M., Cousin, S., Grellety, T., Blay, J-Y., Verret, B., Auzanneau, C., Valade, V., Poignie, L., Lortal, B., Kind, M., Le Loarer, F., Pulido, M.

Get full text

1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network by Blay, J-Y., Italiano, A., Penel, N., Bompas, E., Duffaud, F., Chevreau, C.M., Anract, P., Perrin, C., Firmin, N., Toulmonde, M., Piperno-Neumann, S., Watson, S., Rios, M., Kurtz, J.E., Bertucci, F., Le Loarer, F., Chemin, C., Morelle, M., Gouin, F., Le Cesne, A.

Get full text

1484O Deep learning predicts patients’ outcome and mutations from H&E slides in gastrointestinal stromal tumor (GIST) by Italiano, A., Fu, Y., Karanian, M., Perret, R., Camara, A., Le Loarer, F., Jean-Denis, M., Hostein, I., Michot, A., Ducimetiere, F., Giraud, A., Courreges, J-B., Courtet, K., Laizet, Y., du Terrail, J.O., Schmauch, B., Maussion, C., Blay, J-Y., Coindre, J.M.

Get full text